Schonfeld Strategic Advisors LLC Cidara Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.64 - $0.92 $53,056 - $76,268	-82,900 Reduced 13.06%	552,000 $507,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $0.97 $16,184 - $23,086	23,800 Added 3.89%	634,900 $501,000
Q3 2023 Nov 14, 2023	SELL	$0.77 - $1.16 $26,026 - $39,208	-33,800 Reduced 5.24%	611,100 $574,000
Q2 2023 Aug 14, 2023	SELL	$1.01 - $1.42 $21,715 - $30,530	-21,500 Reduced 3.23%	644,900 $728,000
Q1 2023 May 15, 2023	BUY	$0.75 - $1.98 $499,800 - $1.32 Million	666,400 New	666,400 $846,000
Q2 2022 Aug 15, 2022	SELL	$0.43 - $0.91 $4,687 - $9,919	-10,900 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.67 - $1.39 $7,303 - $15,150	10,900 New	10,900 $9,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.63B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.